

October 29, 2024

To,
The Corporate Relationship Department,
BSE Limited,
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400001
Scrip Code: 540737

Dear Sir / Ma'am,

Sub.: Outcome of Board Meeting held on October 29, 2024.

With reference to the captioned subject matter, we would like to inform you that the Board of Directors of the Company at its meeting held today i.e., October 29, 2024 has inter alia considered and approved the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter and half year ended on September 30, 2024, along with the limited review report of Auditors thereon pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR"). *The copy of the said financial results along with the limited review report of Auditors are enclosed herewith.*

The meeting of the Board of Directors of the Company commenced at 04.30 p.m. and concluded at 06.15 p.m.

Kindly take the same on your record.

Thanking you,
Yours Faithfully,
For Shree Ganesh Remedies Limited

ADITYA
VIKRAMBHAI PATEL
Digitally signed by ADITYA
VIKRAMBHAI PATEL
Date: 2024.10.29 18:36:00
+05'30'

Aditya Patel
Company Secretary

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Shree Ganesh Remedies Limited**

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Shree Ganesh Remedies Limited** ("the Company") for the quarter ended September 30, 2024 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other Matter

5. Read with Note 2 to the accompanying Statement, the comparative financial information of the Company for the quarter ended June 30, 2024, quarter ended September 30, 2023, half year ended September 30, 2023 and year ended March 31, 2024 included in the Statement, have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative financial information for the aforesaid Period expressed an unmodified conclusion/opinion.

Our opinion is not modified in respect of this matter.

For, Chaudhary Shah & Associates LLP
Chartered Accountants
FRN: 006212C/W100789

**SHUBH
AM JAIN**
Digitally signed
by SHUBHAM
JAIN
Date: 2024.10.29
18:28:58 +05'30'

Shubham Jain
Designated Partner
M. No:474949
UDIN: 24474949BKXBIX1390

Place: Ahmedabad
Date: 29.10.2024

INDIA

Independent Auditor's Review Report on Unaudited Quarterly Consolidated Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

**To the Board of Directors,
Shree Ganesh Remedies Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Shree Ganesh Remedies Limited ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended September 30, 2024 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the Entity	Relationship
SGRL USA INC	Wholly Owned Subsidiary [with effect from January 8, 2024 – Refer Note 5(b) to the accompanying Statement]

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. The accompanying Statement includes the unaudited interim financial results/financial information of 1 (one) subsidiary located outside India, whose unaudited interim financial results/financial information reflect total revenue of ₹ NIL lakhs, total net profit/ (loss) after tax (including due to exchange translation) of ₹ (0.98) lakhs and total comprehensive income/(loss) (including due to exchange translation) of ₹ (0.98) lakhs, for the quarter ended September 30, 2024 as considered in the Statement. The management of the Holding Company has prepared and certified the unaudited interim financial results/ financial information of these 1 (one) subsidiary in accordance with Ind AS and accounting principles generally accepted in India, and our opinion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary, is based solely on such financial results/ financial information. In our opinion and according to the information and explanation given to us by the management of the Holding Company, this unaudited interim financial results/ financial information is not material to the Group.
7. The accompanying Statement, the comparative Consolidated financial information of the Company for the quarter ended June 30, 2024 and year ended March 31, 2024 included in the Statement, have been reviewed by the predecessor auditor. The report of the predecessor auditor on the comparative Consolidated financial information for the aforesaid Period expressed an unmodified conclusion/opinion.

Our conclusion on the Statement is not modified in respect of the above matters.

For, Chaudhary Shah & Associates LLP

Chartered Accountants

FRN: 006212C/W100789

SHUBHA Digitally signed by
SHUBHAM JAIN
M JAIN Date: 2024.10.29
18:29:25 +05'30'

Shubham Jain

Designated Partner

M. No:474949

UDIN: 24474949BKXBIY4171

Place: Ahmedabad

Date: 29.10.2024

Statement of Unaudited Financial Results For the Quarter and Half Year Ended September 30, 2024

AMOUNTS ₹ IN LAKHS EXCEPT EPS AND WHERE OTHERWISE STATED

Particular	Sr. No.	Standalone						Consolidated			
		Quarter ended		Half Year ended		Year ended		Quarter ended		Half Year ended	
		September 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)	September 30, 2024 (Unaudited)	September 30, 2023 (Unaudited)	March 31, 2024 (Audited)	September 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	September 30, 2024 (Unaudited)	March 31, 2024 (Audited)
INCOME											
Revenue from Operations	I	3,233.19	2,477.99	3,341.53	5,711.18	6,013.49	12,589.54	3,233.19	2,477.99	5,711.18	12,589.54
Other Income	II	18.82	54.47	80.48	73.29	136.19	306.70	18.82	54.47	73.29	306.70
Total Income (I +II)	III	3,252.01	2,532.46	3,422.01	5,784.47	6,149.68	12,896.24	3,252.01	2,532.46	5,784.47	12,896.24
EXPENSES	IV										
Cost of Materials Consumed		879.51	883.90	1,391.90	1,763.41	3,145.24	6,104.74	879.51	883.90	1,763.41	6,104.74
Purchases of Stock-in-trade		1.23	-	-	1.23	-	127.77	1.23	-	1.23	127.77
Changes in inventories of Finished Goods, Stock-in-trade and Work-in-progress		443.38	(44.85)	407.54	398.53	45.55	(487.91)	443.38	(44.85)	398.53	(487.91)
Employee Benefit Expenses		241.47	235.17	194.32	476.64	353.56	840.58	241.47	235.17	476.64	840.58
Finance Costs		42.82	31.55	1.24	74.37	1.92	59.75	43.80	31.86	75.66	60.72
Depreciation and Amortisation expense		242.40	201.83	140.91	444.23	244.63	610.99	242.40	201.83	444.23	610.99
Other Expenses		536.61	591.37	425.26	1,127.98	850.91	1,823.31	536.61	591.37	1,127.98	1,823.32
Total Expenses (IV)		2,387.42	1,898.97	2,561.17	4,286.39	4,641.82	9,079.24	2,388.40	1,899.28	4,287.67	9,080.21
Profit/(Loss) before Tax (III-IV)	V	864.59	633.49	860.84	1,498.08	1,507.86	3,817.00	863.61	633.18	1,496.80	3,816.03
Tax Expense	VI										
Current Tax		224.37	165.55	198.48	389.92	368.48	933.37	224.37	165.55	389.92	933.37
Deferred Tax		(1.35)	2.75	6.97	1.40	8.87	67.41	(1.35)	2.75	1.40	67.41
(Excess)/Short provision of tax of earlier years		-	-	-	-	-	4.45	-	-	-	4.45
Total Tax Expense (VI)		223.02	168.30	205.45	391.32	377.35	1,005.23	223.02	168.30	391.32	1,005.23
Profit/(Loss) for the period after Tax (V-VI)	VII	641.57	465.19	655.39	1,106.76	1,130.51	2,811.77	640.59	464.88	1,105.48	2,810.80
OTHER COMPREHENSIVE INCOME	VIII										
Items that will not be reclassified to profit or loss											
								0.02	-	0.02	0.03
Remeasurement Gain/ (Loss) on Defined Measurement Benefit Plans		(3.17)	1.00	4.33	(2.17)	4.33	4.01	(3.17)	1.00	(2.17)	4.01
Income Tax Relating to above		0.81	(0.26)	1.09	0.55	1.09	1.01	0.81	(0.26)	0.55	1.01
Total Other Comprehensive Income for the year (VIII)		(2.37)	0.74	5.42	(1.62)	5.42	5.02	(2.34)	0.74	(1.60)	5.05
Total Comprehensive Income for the year (VII+VIII)	IX	639.20	465.93	660.81	1,105.14	1,135.93	2,816.79	638.24	465.62	1,103.87	2,815.85
Earning Per Share of ₹ 10 Par Value	X										
Paid - up Equity Share Capital (Face Value ₹ 10 each)		1,284.34	1,283.76	1,230.93	1,284.34	1,230.93	1,258.31	1,284.34	1,283.76	1,284.34	1,258.31
Basic (In ₹ per share)		4.98	3.62	5.34	8.60	9.18	22.35	4.97	3.62	8.59	22.34
Diluted (In ₹ per share)		4.98	3.62	5.34	8.60	9.18	22.35	4.97	3.62	8.59	22.34

For Shree Ganesh Remedies Ltd.

CHANDULAL
MANUBHAI
KOTHIA

Chandulal Manubhai Kothia

DIN: 00652806

Managing Director

Ankleshwar

October 29, 2024



Head Office (Unit-1) :
Plot No. 6011-12, GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2,-6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1ZQ (Zero)



**SHUBH
AM JAIN**

Digitally signed
by SHUBHAM
JAIN
Date: 2024.10.29
18:29:45 +05'30'

www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
E MAIL

AMOUNTS ₹ IN LAKHS EXCEPT EPS AND WHERE OTHERWISE STATED

Particulars		Standalone		Consolidated	
		As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)	As at September 30, 2024 (Unaudited)	As at March 31, 2024 (Audited)
ASSETS					
1. Non-current Assets					
	(a) Property, Plant and Equipment	5,951.58	4,291.47	5,951.58	4,291.47
	(b) Capital Work-in-progress	257.89	1,662.66	257.89	1,662.66
	(c) Right-of-use Assets	3,730.98	3,756.47	3,730.98	3,756.47
	(d) Other Intangible Assets	5.24	7.05	5.24	7.05
	(e) Intangible Assets under development	35.42	29.42	35.42	29.42
	(f) Financial Assets				
	(i) Investments	16.30	16.30	8.00	8.00
	(ii) Other Financial Assests	201.31	117.95	201.30	117.95
	(g) Other Non-current Assets	310.55	200.39	310.55	200.39
	Total Non-current Assets	10,509.27	10,081.71	10,500.96	10,073.41
2. Current Assets					
	(a) Inventories	1,786.03	2,498.81	1,786.03	2,498.81
	(b) Financial Assets				
	(i) Investments	654.55	465.89	654.55	465.89
	(ii) Trade Receivables	3,177.75	2,033.27	3,177.75	2,033.27
	(iii) Cash and Cash Equivalents	1,458.75	1,577.99	1,464.86	1,585.35
	(iv) Bank Balances other than (iii) of above	7.95	41.00	7.95	41.00
	(v) Other Financial Assets	1.22	2.15	1.22	2.15
	(c) Other Current Assets	195.74	393.63	195.74	393.63
	(d) Current Tax Assets (Net)	41.42	-	41.42	-
	Total Current Assets	7,323.41	7,012.74	7,329.52	7,020.10
	Total Assets	17,832.68	17,094.45	17,830.48	17,093.51
EQUITY AND LIABILITIES					
1. Equity					
	(a) Equity Share Capital	1,284.34	1,284.34	1,284.34	1,284.34
	(b) Other Equity	12,031.57	10,926.43	12,029.37	10,925.49
	Total Equity	13,315.91	12,210.77	13,313.71	12,209.83
2. Liabilities					
(A) Non-current Liabilities					
	(a) Financial Liabilities				
	(i) Borrowings	2,664.84	2,911.85	2,664.84	2,911.85
	(ii) Lease Liabilities	13.26	12.45	13.26	12.45
	(b) Provisions	42.64	33.37	42.64	33.37
	(c) Deferred Tax Liabilities (Net)	58.78	57.94	58.78	57.94
	Total Non-current Liabilities	2,779.53	3,015.60	2,779.53	3,015.60
(B) Current Liabilities					
	(a) Financial Liabilities				
	(i) Borrowings	704.79	719.27	704.79	719.27
	(ii) Lease Liabilities	1.35	1.35	1.35	1.35
	(iii) Trade Payables				
	(a) Total outstanding dues of micro and small enterprises	108.16	116.35	108.16	116.35
	(b) Total outstanding other than (ii) (a) above	778.92	702.40	778.92	702.40
	(iv) Other Financial Liabilities	141.17	180.04	141.17	180.04
	(b) Provisions	2.85	1.92	2.85	1.92
	(c) Current Tax Liabilities (Net)	-	146.75	-	146.75
	Total Current Liabilities	1,737.24	1,868.08	1,737.24	1,868.08
	Total Liabilities	4,516.77	4,883.68	4,516.77	4,883.68
	TOTAL EQUITY AND LIABILITIES	17,832.68	17,094.45	17,830.48	17,093.51

**CHANDULAL
MANUBHAI
KOTHIA**

Digitally signed by CHANDULAL MANUBHAI KOTHIA
DN: cn=O, o=SREER GANESH REMEDIES LTD., ou=DIRECTOR,
2.5.4.20.60.56c4e4b184793f39300ebfd210f420dc4a49,
6eeedf31a7f9d92fc1a8853, postalCode=393002,
st=GUJARAT,
serialNumber=5658d21a2941827a182a142cf151251cf2464ae,
417a7872bbab6ad2071ac5d21, cn=CHANDULAL
MANUBHAI KOTHIA

October 29, 2024



Head Office (Unit-1) :
Plot No. 6011-12, GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1Z0 (Zero)



SHUBH
AM JAIN

www.ganeshremedies.com
 WEBSITE
contact@ganeshremedies.com
 EMAIL

Statement Of Cash Flows as At September 30, 2024

AMOUNTS ₹ IN LAKHS EXCEPT EPS AND WHERE OTHERWISE STATED

Particulars	Standalone		Consolidated
	As at	As at	As at
	September 30, 2024	September 30, 2023	September 30, 2024
	(Unaudited)	(Unaudited)	(Unaudited)
Cash Flow from Operating Activities			
Profit Before Tax	1,498.08	1,507.86	1,496.79
Adjustments for:			
Depreciation and Amortisation	444.23	244.63	444.23
Interest Income	(1.72)	(3.45)	(1.72)
Finance Cost	74.37	1.92	75.66
(Gain)/Loss on Sale of Current Investments	(21.72)	(6.21)	(21.72)
(Gain)/Loss on Sale of Property, Plant and Equipment	(0.06)	-	(0.06)
Unrealized Foreign Exchange Loss/(Gain) (Net)	44.53	-	44.56
Remeasurement of the defined benefit Plans	(2.17)	4.33	(2.17)
Changes in Working Capital			
(Increase) / Decrease in Other Non Current Financial Assets	(10.16)	-	(10.16)
Decrease / (Increase) in Inventories	712.78	(210.50)	712.78
(Increase) / Decrease in Trade Receivables	(1,079.43)	466.58	(1,079.43)
(Increase) / Decrease in Other Current Assets	197.89	(506.28)	197.90
Increase/ (Decrease) in Trade Payables	70.39	(798.97)	70.39
Increase/ (Decrease) in Other Current Financial liabilities	5.37	308.04	5.37
(Decrease)/ Increase in Provisions	10.20	(350.07)	10.20
Income Taxes (Paid) / Refund received	(578.09)	(4.24)	(578.09)
Net Cash Generated / (Used) from Operating Activities (A)	1,364.49	653.63	1,364.52
Cash Flow from Investing Activities			
Investment in Mutual Fund (Net of Proceeds on sale)	(166.94)	-	(166.94)
Sale of Property, Plant and Equipment	1.97	-	1.97
Acquisition of Property Plant and Equipment	(831.37)	(1,199.38)	(831.37)
Interest Income	1.18	-	1.18
Fixed Deposits Matured / (Placed) (Net)	(40.16)	250.00	(40.15)
Net Cash Generated / (Used) from Investing Activities (B)	(1,035.32)	(949.38)	(1,035.31)
Cash Flow from Financing Activities			
Finance Costs	(78.90)	-	(80.18)
Proceeds from / (Repayment of) Secured Loans (Net)	(345.92)	160.13	(345.92)
Proceeds from / (Repayment of) Unsecured Loans (Net)	(66.18)	-	(66.18)
Payment of Lease Liabilities	0.81	-	0.81
Net Cash Generated / (Used) from Financing Activities (C)	(490.19)	160.13	(491.47)
Net increase / decrease in cash and cash equivalents (A+B+C)	(161.02)	(135.62)	(162.26)
Cash and Cash equivalents at the beginning of the period	1,577.99	865.03	1,585.35
Less: Effect of Exchange gain/(loss) on Cash and Cash Equivalents	41.77	-	41.77
Cash and Cash Equivalents at the end of the period	1,458.74	729.41	1,464.86
Particulars	As at	As at	As at
	September 30, 2024	September 30, 2023	September 30, 2024
Cash and Cash Equivalents comprises of:			
Balance with bank			
- In Current Account	1,458.74	701.95	1,464.85
- Working capital facility from bank	-	27.20	-
Cash on hand	0.01	0.26	0.01
Total	1,458.75	729.41	1,464.86

For Shree Ganesh Remedies Ltd.

CHANDULAL
MANUBHAI
KOTHIA

Chandulal Manubhai Kothia

DIN: 00652806

Managing Director

Ankleshwar

October 29, 2024

SHUBH
AM JAIN

Digitally signed by
SHUBHAM JAIN
Date: 2024.10.29
18:30:24 +05'30'



Head Office (Unit-1) :
Plot No. 6011-12, GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076

(Unit-2) :
Plot No. 6714/2, -6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com

UNAUDITED FINANCIAL RESULTS-For The Quarter and Half Year Ended September 30, 2024

ALL AMOUNTS IN LAKHS (₹), EXCEPT SHARE DATA AND WHERE OTHERWISE STATED

Notes:

1. The above results which are published have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 29, 2024. The Financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India. The figures for the quarter ended September 30, 2024 as reported in these financial results are balancing figures between the Unaudited figures for the Half year ended September 30, 2024 and published first Quarter figures for the quarter ended June 30, 2024, which were subjected to limited review.
2. The Company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting".
3. Earnings per share (EPS) is calculated on the weighted average of share capital outstanding during the year as per Ind AS 33 on "Earnings Per Share". EPS for the quarter ended September 30, 2024, June 30, 2024, September 30, 2023, half year ended September 30, 2024 and September 30, 2023 are not annualized.
4. (a) Kamalam Foundation which is incorporated under Section 8 of the Companies Act, 2013 is prohibited to give any right over their profits to its members and accordingly, no share in surplus of Kamalam Foundation is considered to be that of the Company for the purpose of preparation and presentation of consolidated financial results/financial statements/financial information

(b) The Company has incorporated a wholly owned subsidiary, "SGRL USA Inc", and agreed to subscribe its share capital on August 9, 2023. However, since the amount of subscription for share capital was remitted on January 8, 2024, the Company has prepared and presented consolidated financial results for the first time with effect from January 8, 2024 in accordance with Ind AS 110 "Consolidated Financial Statements". Since, the consolidated financial results are being prepared for the first time for the quarter and year ended March 31, 2024, the comparative figures for the quarter ended September 30, 2023 are not prepared and presented.

For Shree Ganesh Remedies Limited

**CHANDULAL
MANUBHAI
KOTHIA**

Digitally signed by CHANDULAL MANUBHAI
KOTHIA
DN: c=IN, o=SHREE GANESH REMEDIES LTD.,
ou=DIRECTOR,
2.5.4.20=a956cc4b14a83793389500b9d21
0fd29de6ca496eedbd33a7d90f29c1a8853,
postalCode=393002, st=GUJARAT,
serialNumber=563b21a2941b71ea142c9f152
510af28c46a417a4b774b3ba4e071ac5fd21,
cn=CHANDULAL MANUBHAI KOTHIA
Date: 2024.10.29 18:14:42 +05'30'

**SHUBH
AM
JAIN**

Digitally signed
by SHUBHAM
JAIN
Date:
2024.10.29
18:30:46 +05'30'

Chandulal Manubhai Kothia

DIN:00652806

Managing Director

Ankleshwar

October 29,2024



Head Office (Unit-1) :
Plot No. 6011-12, GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
CIN No. : L24230GJ1995PLC025661

(Unit-2) :
Plot No. 6714/2,-6715 GIDC Estate,
Ankleshwar - 393 002, Gujarat (INDIA)
Ph.: +91 9614961469, 7574976076
GSTIN : 24ABACS1471R1Z0 (Zero)



www.ganeshremedies.com
WEBSITE
contact@ganeshremedies.com
EMAIL